Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21991

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Pegfilgrastim, Therapeutic Conventional Surgery, Vinblastine Sulfate; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 258
States / cities: Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 197 more

Conditions: Solid Tumors
Interventions: ORIC-114, Chemotherapy drug; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 14 more

Conditions: Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Interventions: PF-08046033; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 2 more

Conditions: Substance Use Disorder (SUD)
Interventions: Regional Anesthesia, Hydromorphone Patient Controlled Analgelsic, Epidural local anesthetic infusion; Drug · Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Epilepsy, Cancer, Brain Neoplasm
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 8 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer, Bladder Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 5,950 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Zika, Influenza
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers, Overweight
Interventions: Sucralose, Placebo; Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postpartum Hypertension
Interventions: Remote Medical Model (RMM), Community Health Model (CHM), SoC; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Worcester, Massachusetts • Buffalo, New York

Conditions: Lung Adenocarcinoma, Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Lung Cancer
Interventions: Biospecimen Collection, Computed Tomography Assisted Biopsy, Dapagliflozin Propanediol, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 22 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Small Cell Lung Cancer
Interventions: Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 16
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 12 more

Conditions: Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Interventions: PF-08046054, Docetaxel monotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 262
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 177 more

Recruiting clinical trials

Filter and sort this status page

Live official records

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications.

Tumor Related Epilepsy

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)